Stock Price Forecast

March 26, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Femasys Inc chart...

About the Company

our experienced management team has over 200 years of collective industry experience with extensive focus in medical devices. the pioneering and collaborative efforts of the management team have created an organization that strives for integrity in all actions, innovation in development activities, excellence in operations, and the highest quality products. the team is complemented by world-class medical advisors. our products have been organically conceived, researched and developed by the company and all manufacturing activities are conducted to ensure compliance with the u.s. food and drug administration (fda) per the requirements of 21 cfr 820, as well as iso 13485. femasys has achieved significant milestones to date, including numerous issued patents and filings, recruitment of a team of experts, clearance of multiple regulatory filings by the u.s. food and drug administration (fda), european union, canada, and japan with other select countries in process. making a difference in t

Exchange

NASDAQ

$1M

Total Revenue

37

Employees

$24M

Market Capitalization

-1.53

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $FEMY News

Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeedĀ® for the Treatment of Infertility

7d ago, source:

In the severe male factor cohort, findings show 24% of women became pregnant after FemaSeed -- -- FemaSeed pregnancy rate by ...

Femasys Announces Positive Data For FemaSeed Trial To Enhance Fertilization In Women

7d ago, source:

The company said the trial investigated its FemaSeed product that enhances fertilization in women with a variety of infertility factors with the primary efficacy analysis focused on the severe male ...

Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution

21d ago, source: Nasdaq

Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting the significant unmet needs for women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and ...

Femasys Welcomes New Chief Commercial Officer Mr. Spector

1mon ago, source: TipRanks on MSN

Femasys (FEMY) has released an update. Femasys Inc. has announced the appointment of Mr. Spector as the new Chief Commercial ...

Femasys' FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF

28d ago, source: Stockhouse

Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting the significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, ...

Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer

1mon ago, source: Morningstar

Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead ...

Femasys Inc.

28d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Femasys Announces Positive Data For FemaSeed Trial To Enhance Fertilization In Women

7d ago, source: Nasdaq

(RTTNews) - Biomedical company Femasys Inc. (FEMY) Wednesday announced positive data from its FemaSeed localized directional insemination for artificial insemination pivotal trial. The company ...

Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution

21d ago, source: Stockhouse

Ongoing uncertainty following recent Alabama Supreme Court Ruling creates continued anticipation with top-line pivotal data expected to be announced during Q1 2024 -- ATLANTA, March 06, 2024 (GLOBE ...

Femasys Inc.: Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed for the Treatment of Infertility

7d ago, source:

In the severe male factor cohort, findings show 24% of women became pregnant after FemaSeed -- -- FemaSeed pregnancy rate by cycle was more than double historic intrauterine insemination (IUI) rate ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...